Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07255768

Comparison of the Efficacy of Pericapsular Nerve Group Block Alone Versus Pericapsular Nerve Group Block Combined With Superior Cluneal and Superior Gluteal Nerve Blocks in Patients Undergoing Hip Surgery

In the clinic, total hip arthroplasty is a frequently performed surgical procedure that often results in moderate to severe postoperative pain. Multimodal analgesia approaches are commonly preferred for managing this pain, and in recent years, nerve blocks targeting pelvic innervation have become increasingly prominent. Among these, the Pericapsular Nerve Group (PENG) block has gained attention for providing effective analgesia by targeting the nerves responsible for the anterior innervation of the hip capsule. However, when used alone, the PENG block may be insufficient for controlling posterior hip pain and may not provide complete analgesia.

In this context, adding blocks targeting the superior cluneal nerve and the superior gluteal nerve-both of which contribute to the sensory innervation of the posterior hip region-has been proposed to enhance the analgesic effect when combined with the PENG block. Superior cluneal and superior gluteal nerve blocks have recently been described in anatomical and clinical studies, and by affecting the structures contributing sensory input to the posterior hip capsule, they hold significant potential for improving pain management.

In this study, the investigators aimed to evaluate the contribution of superior cluneal and superior gluteal nerve blocks, when added to the PENG block, to perioperative analgesia in patients undergoing total hip arthroplasty. The investigators sought to comparatively investigate whether this combination offers superior outcomes compared with the PENG block alone. It was hypothesized that combined nerve blocks may provide similar or improved recovery scores, lower pain scores, reduced opioid consumption, and enhanced analgesic efficacy without affecting the degree of motor blockade.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Voluntary participation in the study
  • Age between 18 and 80 years
  • ASA physical status I, II, or III
  • Male or female patients

Exclusion criteria

  • Refusal to participate in the study
  • Allergy to the medications to be used
  • History of severe cardiac, renal, or hepatic disease
  • Presence of neurological deficits or neuropathy
  • History of anticoagulant use
  • Previous surgery in the inguinal or suprainguinal region
  • Pregnancy
  • Chronic opioid use at home
  • History of spinal surgery

Treatment and study plan

15 ml Bupivacaine Hcl 0.25% injection

Drug

For PENG Block, 15 mL of 0.25% bupivacaine will be administered.

20 mL bupivacaine 0.25% injection

Drug

After performing PENG; 10 mL of 0.25% bupivacaine will be administered for each superior cluneal nerve block and superior gluteal nerve block

Primary outcomes

  1. QoR-15 (Quality of Recovery-15) questionnaire

    Time frame: 24th and 48th postoperative hour

    The primary outcome measure will be the QoR-15 (Quality of Recovery-15) questionnaire administered at the 24th postoperative hour. QoR-15 is a validated 15-item short survey assessing patients' postoperative physical comfort, emotional state, level of independence, pain control, and overall well-being. The total score obtained will be used to compare the overall quality of recovery between groups. The same questionnaire will be repeated at the 48th postoperative hour.

Secondary outcomes

  1. Quadriceps Motor Block Assessment

    Time frame: It will be assessed at the 4th, 8th, 12th, and 24th postoperative hours.

    Motor block will be assessed using the following 3-point scale:

    0 = Normal strength (dorsiflexion against gravity and resistance)

    • = Paresis (dorsiflexion against gravity only, not against resistance)
    • = Paralysis (dorsiflexion not possible)
  2. Motor Block Assessment at the Tibialis Anterior Muscle for the Sciatic Nerve

    Time frame: It will be assessed at the 4th, 8th, 12th, and 24th postoperative hours.

    Motor block will be assessed using the following 3-point scale:

    0 = Normal strength (dorsiflexion against gravity and resistance)

    • = Paresis (dorsiflexion against gravity only, not against resistance)
    • = Paralysis (dorsiflexion not possible)
  3. Fentanyl consumption

    Time frame: The first 24 postoperative hours

    Fentanyl consumption will be recorded via the PCA device during the postoperative intervals of 0-4, 4-8, and 8-24 hours. Total opioid consumption will be calculated at the 24th postoperative hour.

  4. VAS pain scores

    Time frame: The first 24 postoperative hours

    VAS pain scores will be assessed at the 1st, 2nd, 4th, 8th, 12th, and 24th postoperative hours, both at rest and during movement. The region where the patient experiences the most intense pain will be recorded as either the anterior or posterior hip.

Sponsors and collaborators

Lead sponsor

Ataturk University

Other

Registry information

Official study title

Comparison of the Efficacy of Pericapsular Nerve Group Block Alone Versus Pericapsular Nerve Group Block Combined With Superior Cluneal and Superior Gluteal Nerve Blocks in Patients Undergoing Hip Surgery: A Prospective Randomized Clinical Study

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 1, 2025
Registry last updated
Dec 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.